CUE-101
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Oropharyngeal Squamous Cell Carcinoma
Conditions
Oropharyngeal Squamous Cell Carcinoma
Trial Timeline
Dec 6, 2021 → Oct 31, 2027
NCT ID
NCT04852328About CUE-101
CUE-101 is a phase 2 stage product being developed by Cue Biopharma for Oropharyngeal Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04852328. Target conditions include Oropharyngeal Squamous Cell Carcinoma.
What happened to similar drugs?
0 of 2 similar drugs in Oropharyngeal Squamous Cell Carcinoma were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04852328 | Phase 2 | Recruiting |
Competing Products
12 competing products in Oropharyngeal Squamous Cell Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Phase 1 | 29 |
| Cetuximab + Cisplatin | Eli Lilly | Phase 2 | 27 |
| Durvalumab + Tremelimumab | AstraZeneca | Phase 1/2 | 24 |
| Cisplatin + Durvalumab + Tremelimumab | AstraZeneca | Phase 2 | 39 |
| Cisplatin + Durvalumab | AstraZeneca | Phase 3 | 44 |
| Chemoradiotherapy arm + Immunotherapy + Radiotherapy arm | AstraZeneca | Phase 2 | 35 |
| MEDI0457 + Durvalumab | AstraZeneca | Phase 2 | 27 |
| VB10.16 + Pembrolizumab | Merck | Phase 1/2 | 39 |
| Cetuximab | Merck | Phase 2 | 31 |
| 9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) | Merck | Phase 3 | 44 |
| Paclitaxel + Carboplatin + Nivolumab | Bristol Myers Squibb | Phase 2 | 35 |
| Cyclophosphamide + IRX-2 + Nivolumab | Bristol Myers Squibb | Phase 1 | 21 |